Boston University School of Medicine Awarded More Than $700,000 for Non-Hodgkin’s Lymphoma Research
Contact: Kristen Perfetuo, 617-638-8491 | firstname.lastname@example.org
(Boston) — Boston University School of Medicine (BUSM) has been awarded a four-year, $720,000 grant from the American Cancer Society to support ongoing research on a gene linked to non-Hodgkin’s Lymphoma (NHL), a cancer that starts in the lymph nodes. More than 50,000 Americans will be newly diagnosed with NHL this year.
Led by Gerald Denis, Ph.D., assistant professor of pharmacology and medicine at BUSM, a research team will investigate the function of the brd2 gene in non-Hodgkin’s Lymphoma and will try to eliminate the gene using state-of-the-art molecular technology. Their findings could help scientists identify new, pre-malignant markers of lymphoma and leukemia, according to Denis.
“Learning more about this gene will contribute not only to a deeper understanding of NHL, but of all cancer mechanisms,” said Denis. “We are thankful to the American Cancer Society for this generous grant, which will help us continue our studies and hopefully allow us to develop new cancer-fighting therapies.”
Apart from genetic studies, BUSM researchers will also use a highly sophisticated instrument system known as mass spectrometry to analyze complex molecules responsible for causing non-Hodgkin’s Lymphoma.
“Using this technology, we have been able to define some of the complex mechanisms that trigger this disease,” added Denis. “These mechanisms are novel and potentially important players in the cancer process. We are excited to be pioneers in this area.”